Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Smart Money Circle

Smart Money Circle artwork

This Biotech CEO Is Architecting Bioregeneration – Meet Miles Harrison CEO - Conexu Sciences $CNXU

Nov 9, 202623 minAudio
ShareXLinkedInFacebookWhatsAppEmail

This Biotech CEO Is Architecting Bioregeneration - Meet Miles Harrison President and CEO - Conexu Sciences $CNXU Guest: Miles Harrison President and CEO - Conexu Sciences $CNXU Bio: Miles Harrison President and CEO, Director Miles Harrison is a healthcare and aesthetics executive with a proven record of scaling global businesses, driving innovation, and creating shareholder value. He currently serves on the Board of Castle Biosciences (NASDAQ: CSTL), and sits on the Compensation Committee and Nominating and Governance Committee, Castle Biosciences provides test solutions for the diagnosis and treatment of dermatologic cancers. Previously, Miles co-founded and led Novaestiq Corp., building a novel aesthetics platform, raising multi-millions in early financing, and securing strategic distribution with Croma Pharma in North America. He successfully positioned Novaestiq for a significant strategic exit in 2025. Before Novaestiq, Miles was President & General Manager, North America at Galderma, leading three business units - Aesthetics, Consumer, and Prescription - across North America, with an expansive employee base and over $1.2B in revenue. He drove sustained growth and margin expansion, and scaled several iconic consumer, aesthetic and prescription brands including Cetaphil®, Differin®, Dysport®, Sculptra®, Restylane® and Epiduo®. Miles was part of the executive leadership team that supported EQT’s multi billion dollar acquisition of Galderma in late 2019. Earlier, at Nestlé Skin Health, he built the U.S. Consumer Business Unit from the ground up, delivering double-digit organic growth and leading the first FDA-approved RX-to-OTC acne switch in 30 years (Differin® Gel). Miles seeks to bring a blend of boardroom discipline and entrepreneurial drive to his next role as CEO of Conexeu™ Sciences Inc. Known for building high-performing teams and shaping cultures that thrive under change, he combines governance depth, capital strategy expertise, and hands-on operating leadership. At Conexeu™, he will lead the charge to bring first-in-class disruptive human collagen technologies to market across aesthetics, wound care, and regenerative medicine - pioneering a category that sits at the intersection of science, patient impact, and long-term value creation. Conexecu Sciences Inc. Nasdaq: CNXU https://www.conexeu.com/ About Conexeu Sciences Inc. Architecting BioregenerationTM. Conexeu Sciences is a preclinical-stage regenerative tissue platform company. Our patented extracellular matrix (ECM) platform, CXU™, is built on a single structural principle and is designed to support bioregeneration: one formula, one device, designed to scale across multiple addressable markets. Conexeu is targeting large, multi-billion-dollar end markets, including wound care, periodontal applications, and facial and body tissue restoration, including the tissue changes that can follow GLP-1 weight loss, with further expansion opportunities in 3D printing and biofabrication workflows and the veterinary market. The Company is advancing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review. Conexeu is led by an experienced leadership team with deep expertise in biomaterials, regenerative medicine, and medical device commercialization and development.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. How This $53 Billion ETF Company Innovates In Today’s Market

    Nov 18, 202614 minAudio

    Guest Matt Kaufman, Global Head of ETFs at Calamos Investments Calamos Investments $53 Billion in AUM Including $25 Billion in liquid alternatives (as of 9/30/26) https://www.calamos.com/ About Matt Matt Kaufman serves...

    Credit the people on this episode

  2. Autonomous Trucks Are Here & Transportation Should Be Safe & Efficient For Everyone – Meet Don Burnette CEO Kodiak AI – KDK

    Nov 3, 202622 minAudio

    Credit the people on this episode

  3. The CIO Of A $10 Billion Firm Shares Timeless Advice - Stuart Katz, Robertson Stephens

    Oct 20, 202614 minAudio

    Timeless Advice From The Chief Investment Officer Of A $10 Billion Firm Meet Stuart Katz, Chief Investment Officer, Robertson Stephens (AUM: $9.5B) Bio Stuart Katz creates and leads the firm’s investment strategy,...

    Credit the people on this episode

  4. $3 Billion Money Manager Never Interrupt Compounding – Isaac Wakszol CEO Activest Wealth Management

    Oct 16, 202618 minAudio

    Guest Isaac Wakszol is the CEO of Activest Wealth Management Company Activest Wealth Management Website https://activestwm.com/ Assets 3B AUA 1.7B AUM Isaac’s Bio Before founding Activest, he represented a Swiss private...

    Credit the people on this episode

  5. Is Lidar The Future Of Autonomous Driving? Meet Matt Fisch CEO AEYE $LIDR

    Oct 15, 202615 minAudio

    This CEO Is Using Lidar To help Autonomous Driving- Meet Matt Fisch CEO AEYE $LIDR Matt Fisch Chairman & Chief Executive Officer, AEye, Inc. $LIDR Matt Fisch is Chief Executive Officer of AEye, Inc. (NASDAQ: LIDR), a...

    Credit the people on this episode